company background image
NYKD

Nykode Therapeutics OB:NYKD Stock Report

Last Price

kr35.00

Market Cap

kr10.3b

7D

18.1%

1Y

-56.7%

Updated

23 May, 2022

Data

Company Financials +
NYKD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NYKD Stock Overview

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.

Nykode Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Nykode Therapeutics
Historical stock prices
Current Share Pricekr35.00
52 Week Highkr89.50
52 Week Lowkr27.52
Beta1.55
1 Month Change-14.59%
3 Month Change-20.46%
1 Year Change-56.68%
3 Year Changen/a
5 Year Changen/a
Change since IPO76.77%

Recent News & Updates

Shareholder Returns

NYKDNO BiotechsNO Market
7D18.1%7.7%2.1%
1Y-56.7%-47.8%12.3%

Return vs Industry: NYKD underperformed the Norwegian Biotechs industry which returned -47.8% over the past year.

Return vs Market: NYKD underperformed the Norwegian Market which returned 12.3% over the past year.

Price Volatility

Is NYKD's price volatile compared to industry and market?
NYKD volatility
NYKD Average Weekly Movement12.9%
Biotechs Industry Average Movement8.3%
Market Average Movement7.5%
10% most volatile stocks in NO Market13.0%
10% least volatile stocks in NO Market4.3%

Stable Share Price: NYKD is more volatile than 75% of Norwegian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: NYKD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

FoundedEmployeesCEOWebsite
2007128Michael Engsighttps://nykode.com

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10

Nykode Therapeutics Fundamentals Summary

How do Nykode Therapeutics's earnings and revenue compare to its market cap?
NYKD fundamental statistics
Market CapUS$1.05b
Earnings (TTM)-US$9.80m
Revenue (TTM)US$36.01m

28.9x

P/S Ratio

-106.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NYKD income statement (TTM)
RevenueUS$36.01m
Cost of RevenueUS$0
Gross ProfitUS$36.01m
Other ExpensesUS$45.82m
Earnings-US$9.80m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 24, 2022

Earnings per share (EPS)-0.034
Gross Margin100.00%
Net Profit Margin-27.23%
Debt/Equity Ratio0%

How did NYKD perform over the long term?

See historical performance and comparison

Valuation

Is Nykode Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


5.51x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: NYKD (NOK35) is trading above our estimate of fair value (NOK8.93)

Significantly Below Fair Value: NYKD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: NYKD is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: NYKD is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NYKD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NYKD is overvalued based on its PB Ratio (5.5x) compared to the NO Biotechs industry average (4x).


Future Growth

How is Nykode Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


125.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NYKD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NYKD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NYKD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NYKD's revenue (77% per year) is forecast to grow faster than the Norwegian market (1% per year).

High Growth Revenue: NYKD's revenue (77% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NYKD's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nykode Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


59.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NYKD is currently unprofitable.

Growing Profit Margin: NYKD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NYKD is unprofitable, but has reduced losses over the past 5 years at a rate of 59.4% per year.

Accelerating Growth: Unable to compare NYKD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYKD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: NYKD has a negative Return on Equity (-5.2%), as it is currently unprofitable.


Financial Health

How is Nykode Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: NYKD's short term assets ($244.1M) exceed its short term liabilities ($31.1M).

Long Term Liabilities: NYKD's short term assets ($244.1M) exceed its long term liabilities ($34.3M).


Debt to Equity History and Analysis

Debt Level: NYKD is debt free.

Reducing Debt: NYKD has not had any debt for past 5 years.

Debt Coverage: NYKD has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NYKD has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Nykode Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NYKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NYKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NYKD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NYKD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NYKD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Michael Engsig

2.67yrs

Tenure

Mr. Michael Thyring Engsig has been Chief Executive Officer of Nykode Therapeutics AS (formerly known as Vaccibody AS) since September 1, 2019. Mr. Engsig joined Nykode Therapeutics AS in March 2017 and se...


Leadership Team

Experienced Management: NYKD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: NYKD's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NYKD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Nykode Therapeutics AS's employee growth, exchange listings and data sources


Key Information

  • Name: Nykode Therapeutics AS
  • Ticker: NYKD
  • Exchange: OB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr10.286b
  • Shares outstanding: 289.92m
  • Website: https://nykode.com

Number of Employees


Location

  • Nykode Therapeutics AS
  • Oslo Research Park
  • Gaustadalleen 21
  • Oslo
  • Oslo
  • 349
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.